Document is current
Any future updates will be listed below
-
Authors
Mosconi, Paola
Colombo, Cinzia
Paletta, Pasquale
Gangeri, Laura
Pellegrini, Chiara
Garralda, Elena
Miceli, Rosalba
Brunelli, Cinzia
,
Braña, Irene
Rodon, Jordi
Villacampa, Guillermo
Pedrola, Anna
Dienstmann, Rodrigo
Pont, Bianca
Lostes, Júlia
Piris, Alejandro
Chavarria, Elena
Villalobos, Xenia
Colldeforns, Berta
Pérez-López, Raquel
Nuciforo, Paolo
Tamborero, David
Lehtiö, Janne
Razzak, Ali
Pernemalm, Maria
Jonsson, Markus
Rachid, Maan
Boekel, Jorrit
de Petris, Luigi
Von Gertten, Christina
Bäckvall, Helena
Von Witting, Maria
He, Xiaobing
Baird, Richard
Jaki, Thomas
Jodrell, Duncan
Doherty, Gary
Pacey, Simon
Bradley, Rebecca
Gallagher, Ferida
Woitek, Ramona
Beddowes, Emma
Anand, Shubha
Honan, Katherine
Zheng, Haiyan
Mozgunov, Pavel
Demetris, Nikos
Donoghue, Kate
Seamon, Kenneth
Escudero, Lorena
Burton, Melanie
Arponen, Otso
Fröhling, Stefan
Schlenk, Richard
Oberrauch, Petra
Molnar, Anett
Störzel, Manuel
Maier-Hein, Klaus
Sedlaczek, Oliver
Schlemmer, Heinz-Peter
Horak, Peter
Nolden, Marco
Kreutzfeldt, Simon
Schlander, Michael
Schader, Philipp
Muchandifung, Muchadeyi
Wessely, Jennifer
Opdam, Frans
Beets-Tan, Regina
Bodalal, Zuhir
Weijer, Ruud
Apolone, Giovanni
Scoazec, Giovanni
Vernieri, Claudio
Leporati, Rita
Agnelli, Luca
Vingiani, Andrea
Antioco, Mikol
Damian, Silvia
Duca, Matteo
De Braud, Filippo
Villa, Andrea
Alfieri, Sara
Forest, Arnauld
Lauden, Laura
Deloger, Marc
Loriot, Yohan
Pailler, Emma
Fitzpatrick, Paul
Freitas, André
Dwan, Ciara
Graham, Donna
Frost, Hannah
Goodwin, Leanna
Bogatu, Alex
Wysocki, Oskar
Wysocka, Magdalena
van Hagen, Sjoerd
Leenknegt, Bas
Rodenburg, Sander
Garcia, Elena
van Nierop, Pim
Orsini, Mirko
Monari, Marco
Pacchioni, Marco
Mescoli, Emma
Calanchi, Enrico
-
Funding
Funding for this research was provided by:
European Union’s Horizon 2020 research and innovation programme (No 965397, No 965397, No 965397, No 965397, No 965397, No 965397, No 965397, No 965397)
- License Information
-
More Information
Article History
Received: 21 April 2023
Accepted: 5 August 2023
First Online: 30 August 2023
Declarations
:
: All the methods and procedures were performed in accordance with the guidelines and ethical standards and with the 1964 Helsinki Declaration and its later amendments. The study was approved by the Ethical Committee of the Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (INT 205/21). Informed consent was obtained from all subjects, participation was voluntary and respondents were asked to give their consent to participate in the first question of the survey. Respondents were informed that data were not collected anonymously as the small sample size by center did not allow proper anonymization. Responses were treated confidentially in agreement with the European General Data Protection Regulation (GDPR-Regulation EU 2016/679) and the results are presented only in aggregate form.
: Not applicable.
: PM, CC, PP, LG, CP, RM and CB report no conflicts of interest.EG reports: Grants or contracts from Novartis / Roche / Thermo Fisher / AstraZeneca / Taiho / BeiGene / Janssen; Consulting fees from Roche/Genentech - F.Hoffmann/La Roche - Ellipses Pharma - Neomed Therapeutics1 Inc - Boehringer Ingelheim - Janssen Global Services – SeaGen – Alkermes – Thermo Fisher - Bristol-Mayers Squibb – MabDiscovery – Anaveon – F-Star Therapeutics – Hengrui – Sanofi; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Merck Sharp & Dohme / Roche / Thermo Fisher / Lilly / Novartis; Other financial or non-financial interests as PI or Co-PI-Institutional from Adaptimmune LLC - Affimed Gmbh - Amgen SA – Anaveon AG – AstraZeneca AB – Bicycletx Ltd – BioInvent International AB – Biontech SE - Biontech Small Molecules Gmbh – Boehringer Ingelhem International Gmbh - Catalym Gmbh - Cyclacel Biopharmaceuticals – Cytovation AS - Cytomx – F.Hoffmann La Roche Ltd – F-Star Beta Limited - Genentech Inc - Genmab B.V. – Hifibio Therapeutics - Hutchison Medipharma Limited – Icon - Imcheck Therapeutics – Immunocore Ltd - Incyte Corporation – Incyte Europe Sàrl - Janssen-Cilag International NV - Janssen-Cilag SA – Laboratorios Servier SL - Medimmune Llc – Merck & Co, Inc – Merck Kgga - Novartis Farmacéutica, S.A – Peptomyc – Pfizer Slu – Relay Therapeutics – Replimmune - Ribon Therapeutics – Ryvu Therapeutics SA – Seattle Genetics Inc – Sotio as – Sqz Biotechnologies - Symphogen A/S – Taiho Pharma Usa Inc – T-Knife Gmbh.
